Ticker brief
RCKT
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
5
authors 14d
5
crowd 14d
+0.4σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-06 → 2026-10-07 · now +0.26 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @zohmbastic | C | -2.94 | 1 | +0.15 |
| @Quantumup1 | C | +0.10 | 1 | +0.40 |
| @Analytica_X | B | -0.29 | 1 | +0.25 |
| @OzmosiHealth | C | · | 1 | +0.25 |
| @BiopharmIQ | B | · | 1 | +0.15 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-07 | @BiopharmIQ | +0.15 | Summarizes positive midday biotech stock moves alongside company catalysts. | · | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.25 | Highlights an FDA-aligned pivotal Phase 2 trial and updated RP-A501 findings. | · | tweet ↗ |
| 2026-10-07 | @Analytica_X | +0.25 | Watchlist summarizes regulatory, asset-sale, FDA and financing catalysts across four companies. | · | tweet ↗ |
| 2026-10-07 | @Quantumup1 | +0.40 | Cantor reiterates RCKT at Overweight with a $15 target after a program update. | · | tweet ↗ |
| 2026-10-06 | @zohmbastic | +0.15 | Rocket entered a Hercules Capital credit facility for up to $150M to fund clinical development. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.